NASDAQ:KTTA Pasithea Therapeutics - KTTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $0.70 +0.04 (+6.03%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.65▼$0.7350-Day Range$0.55▼$1.0352-Week Range$0.54▼$1.54Volume552,642 shsAverage Volume123,073 shsMarket Capitalization$20.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Pasithea Therapeutics (NASDAQ:KTTA) StockPasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.Read More Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KTTA Stock News HeadlinesJanuary 25, 2023 | seekingalpha.comKTTA Pasithea Therapeutics Corp.January 23, 2023 | americanbankingnews.comPasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Significant Drop in Short InterestJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 18, 2023 | finance.yahoo.comPasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004January 16, 2023 | finance.yahoo.comPasithea Therapeutics Corp. (KTTA)December 14, 2022 | finance.yahoo.comMajority of Stockholders Support Pasithea Directors at Special MeetingDecember 6, 2022 | finance.yahoo.comPasithea Therapeutics to Present at Annual Meeting of the Antibody Society ConferenceNovember 28, 2022 | finance.yahoo.comPasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern TimeJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 22, 2022 | finance.yahoo.comInvestor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea TherapeuticsOctober 17, 2022 | finance.yahoo.comPasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and SymposiumOctober 14, 2022 | finance.yahoo.comPasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly DilutiveOctober 13, 2022 | finance.yahoo.comInvestor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek TherapeuticsOctober 12, 2022 | finance.yahoo.comPasithea Therapeutics Acquires AlloMek TherapeuticsOctober 10, 2022 | markets.businessinsider.comEQS-News: New Drugs And Therapies Are Giving MS And ALS Sufferers New HopeOctober 10, 2022 | finance.yahoo.comNew Drugs And Therapies Are Giving MS And ALS Sufferers New HopeOctober 5, 2022 | nasdaq.comWe're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn RateOctober 3, 2022 | finance.yahoo.comPasithea Therapeutics to Call Special Meeting of StockholdersOctober 3, 2022 | markets.businessinsider.comEQS-News: Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple SclerosisSeptember 28, 2022 | finance.yahoo.comInvestor Group Sends Letter to Pasithea Therapeutics’ Board of DirectorsSeptember 15, 2022 | finance.yahoo.comPasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit CudkowiczSeptember 12, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn SituationSeptember 6, 2022 | finance.yahoo.comInvestor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea TherapeuticsAugust 24, 2022 | finance.yahoo.comInvestor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special MeetingAugust 18, 2022 | finance.yahoo.comPasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy ConferenceAugust 11, 2022 | finanznachrichten.deFinancialnewsmedia.com: Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029August 11, 2022 | seekingalpha.comPasithea jumps 21% on animal data for multiple sclerosis candidateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KTTA Company Calendar Today1/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KTTA CUSIPN/A CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,170,000.00 Net Margins-3,133.55% Pretax Margin-3,133.55% Return on Equity-16.40% Return on Assets-15.82% Debt Debt-to-Equity RatioN/A Current Ratio29.37 Quick Ratio29.37 Sales & Book Value Annual Sales$20,000.00 Price / Sales1,027.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book0.32Miscellaneous Outstanding Shares29,250,000Free Float27,348,000Market Cap$20.56 million OptionableNot Optionable Beta-0.04 Key ExecutivesDr. Lawrence Steinman BA (Age 74)M.D., Exec. Chairman & Co-Founder Comp: $72.92kDr. Tiago Reis Marques (Age 45)CEO & Director Comp: $243.75kMr. Daniel H. Schneiderman (Age 44)Chief Financial Officer Dr. Yassine Bendiabdallah Ph.D. (Age 37)COO & Head of UK Clinics Key CompetitorsForte BiosciencesNASDAQ:FBRXeFFECTOR TherapeuticsNASDAQ:EFTRFlora GrowthNASDAQ:FLGCTempest TherapeuticsNASDAQ:TPSTMetacrineNASDAQ:MTCRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 81,705 shares on 11/15/2022Ownership: 0.599%David DelaneyBought 1,000 shares on 10/17/2022Total: $1,110.00 ($1.11/share)Eric ShahinianBought 57,647 shares on 9/28/2022Total: $68,599.93 ($1.19/share)Eric ShahinianBought 5,000 shares on 8/29/2022Total: $5,850.00 ($1.17/share)Avi GellerBought 54,644 shares on 8/19/2022Total: $71,037.20 ($1.30/share)View All Insider TransactionsView All Institutional Transactions KTTA Stock - Frequently Asked Questions How have KTTA shares performed in 2023? Pasithea Therapeutics' stock was trading at $0.6417 at the beginning of the year. Since then, KTTA stock has increased by 9.5% and is now trading at $0.7029. View the best growth stocks for 2023 here. When did Pasithea Therapeutics IPO? (KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share. What is Pasithea Therapeutics' stock symbol? Pasithea Therapeutics trades on the NASDAQ under the ticker symbol "KTTA." How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pasithea Therapeutics' stock price today? One share of KTTA stock can currently be purchased for approximately $0.70. How much money does Pasithea Therapeutics make? Pasithea Therapeutics (NASDAQ:KTTA) has a market capitalization of $20.56 million and generates $20,000.00 in revenue each year. How can I contact Pasithea Therapeutics? Pasithea Therapeutics' mailing address is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. The official website for the company is www.pasithea.com. The company can be reached via phone at 702-514-4174 or via email at lwilson@insitecony.com. This page (NASDAQ:KTTA) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.